Evaluation of serum Podocalyxin in Iraqi women with Polycystic Ovary Syndrome
DOI:
https://doi.org/10.32007/jfacmedbagdad.6441983Keywords:
PCOS, polycystic ovary syndrom, PODXL, BMI, WC, WHR, obesityAbstract
Background: Polycystic ovarian syndrome is the most common endocrine disease in females of childbearing time of life. Women with polycystic ovarian syndrome have a higher chance of developing complications such as dyslipidemia, hypertension, and obesity. Obesity is a state of extreme fat buildup which leads to the development of multiple complications involving non-alcoholic fatty liver disease, cardiovascular disease and type2 diabetes mellitus. Podocalyxin is an element of the endothelial cells plasma membranes that is widely spread, it is limited to the luminal membrane area and is irregularly located on the surface of endothelial cells lining blood vessels.
Objectives: To estimate serum Podocalyxin in polycystic ovarian syndrome women and compare its level with healthy controls. Also, to find the correlation between serum Podocalyxin and anthropometrics parameters which are (body mass index, waist circumference, waist to hip ratio).
Methods: This case control study included 124 women who were grouped into 2 groups: group 1 included 63 females diagnosed with PCOS (patients) and group 2 included 61 healthy women (controls). Serum podocalyxin was measured by Enzyme-linked immunosorbent assay technique and anthropometrics measures (“body mass index (BMI), waist circumference (WC) and waist to hip ratio WHR”) were done.
Results: The results of this study showed significantly high mean BMI(P=0.001), WC(P=0.002) and WHR(P=0.001) in patients as compared to healthy controls. The results also showed a significant increase in mean value of serum PODXL (P=0.001) in PCOS females when compared with healthy controls. In patients group, significant positive correlations were found between serum PODXL and BMI (r=0.395, p=0.001), waist circumference (WC) (r.=0.433, p.=0.001) and waist to hip ratio (WHR) (r.=0.427, p.=0.001 ).
Conclusion: PCOS women have greater body mass represented by BMI, WC and WHR which reflect the risk of multiple complications like hypertension, dyslipidemia and cardiovascular disease. Moreover, PCOS women have higher serum PODXL which is considered as a marker for the vasculature thus might be a potential marker for prediction of early atherosclerosis.
Downloads
References
Louwers YE and Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 2020; 14: 1-9.
Hamdi RA, Abdul-Qahar ZH, Kadhum EJ and Alsaeed FA. Assessment of Serum Vitamin D Levels in Women with Polycystic Ovary Syndrome. J Fac Med Baghdad. 2018; 60(2): 93-97.
Mu L, Li R, Lai Y, Zhao Y and Qiao J. Adipose insulin resistance is associated with cardiovascular risk factors in polycystic ovary syndrome. J Endocrinol Invest. 2019; 42(5): 541-548.
Lee J and Kim JH. Endocrine comorbidities of pediatric obesity. Clin Exp Pediatr. 2021; 64(12): 619-627.
Powell-Wiley TM, Poirier P, Burke LE, Després J P, Gordon-Larsen, P et al.. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021; 143(21): 984-1010.
Le Tran N, Wang Y and Nie G . Podocalyxin in Normal Tissue and Epithelial Cancer. Cancers. 2021; 13(12): 2863.
Horvat R, Hovorka A, Dekan G, Poczewski H and Kerjaschki D. Endothelial Cell Membranes Contain Podocalyxin the Major Sialoprotein of Visceral Glomerular Epithelial Cells. J Cell Biol. 1986; 102(2): 484-491
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81, 19-25. [PubMed]
WHO (2000). Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization.
Witchel SF, Oberfield SE and Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc. 2019; 3(8): 1545-1573.
Goodarzi MO, Dumesic DA, Chazenbalk G and Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4): 219-231.
Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med. 2008; 26(1): 39-44.
Shamam KH, El – Yassin HD and Al – Shammaa H. Serum resistin levels, and other hormonal and biochemical parameters in patients with polycystic ovary syndrome (PCOS). Fac Med Baghdad, 2009; 51(2): 200-203.
Majeed S, Rabia A, Aysha M, Tooba J and Sidra A. Indicators of Obesity and Cardiovascular Parameters in Obese and Non-Obese Subjects. Pakistan J Medical Health Sci. 2021; 15(10): 3413-3416.
Mandviwala T, Khalid U and Deswal A. Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?. Curr Atheroscler Rep. 2016; 18(5): 21.
Ilhan AG and Yildizhan B. Podocalyxin a new biomarker in polycystic ovary syndrome. Fertil Steril. 2018; 110(4): 117-118.
Shoji M, Takemoto M, Kobayashi K, Shoji T, Mori S, Sagara JI et al.. Serum podocalyxin levels correlate with carotid intima media thickness, implicating its role as a novel biomarker for atherosclerosis. Sci Rep. 2018; 8(1): 245.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Noor Mohammed Fadhil, Rana ali hamdi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Creative Commons Attribution 4.0 International license..
